Body Composition

Semaglutide

Semaglutide (GLP-1 Receptor Agonist)

The benchmark GLP-1 agonist behind a generation of metabolic research

Research Status: FDA-approved (T2D & obesity); landmark STEP/SUSTAIN trials Ozempic Wegovy Rybelsus
Mechanism of Action

How it works

Semaglutide mimics the incretin hormone GLP-1, binding its receptor to enhance glucose-dependent insulin release, suppress glucagon, slow gastric emptying, and reduce appetite via central pathways. Structural modifications give it a long half-life.

Areas of Research

What the research explores

In published research, Semaglutide has been studied in connection with the following. These describe findings reported in the literature — not approved uses, claims, or outcomes to expect.

  • Among the most-studied compounds for weight management
  • Improves glycemic and HbA1c markers in trials
  • Reduces appetite and caloric intake in research
  • Investigated for cardiovascular outcomes
  • Broad Phase III evidence base
Research Highlight

The STEP trials established clinically meaningful mean weight loss with weekly semaglutide, reshaping the obesity-pharmacology field.

Safety Profile

Adverse events & gaps

Extensively characterized. Gastrointestinal effects are the most commonly reported and are usually transient and dose-related.



Stay Informed on
Peptide Research

Research summaries, newly documented peptides, and clinical trial updates delivered to your inbox.

No spam. Unsubscribe at any time.